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Objectives. We investigated the patterns of perfusion and
metabolism in dysfunctional myocardium whose contractility im-
proved with dobutamine.
Background. Clinical studies have suggested that dobutamine
echocardiography can identify hibernating myocardium, but lab-
oratory studies suggest that reduced perfusion limits the response
to dobutamine.
Methods. Twenty-five patients with coronary disease and ven-
tricular dysfunction underwent low (5 and 10 mg/kg body weight
per min) and high dose (maximum of 50 mg/kg per min) dobut-
amine echocardiography and positron emission tomography
(PET) using nitrogen-13 (N-13) ammonia and fluorine-18 fluoro-
deoxyglucose (FDG) for imaging of perfusion and metabolism.
Wall motion and tracer uptake were scored in 16 left ventricular
segments.
Results. Perfusion and metabolism were normal in 56.4%,
mildly reduced in 29.1% and mismatched (reduced perfusion,
preserved FDG uptake) in 14.5% of dysfunctional segments viable
on PET. Wall motion improved with dobutamine in 89 dysfunc-
tional segments (62 at low dose, 27 only at peak dose), and 86 of
these (97%) were viable on PET. Improvement in wall motion with
dobutamine was more common in segments with normal perfu-
sion and metabolism (56.5%) than in those with mildly reduced
tracer uptake (28.5%, p < 0.001) and those with mismatch (32%,
p5 0.03). All the segments with a biphasic response were supplied
by vessels with >270% stenosis, and 88% had normal perfusion and
metabolism.
Conclusions. The majority of viable segments with rest dysfunc-
tion had normal perfusion and metabolism, suggesting that
myocardial stunning was common. Improvement of wall motion at
low and high doses of dobutamine was highly correlated with
myocardial viability on PET and was more common in myocar-
dium with normal perfusion. A biphasic response to dobutamine
identified segments with normal perfusion and metabolism sup-
plied by severely diseased vessels.
(J Am Coll Cardiol 1997;29:55–61)
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Dobutamine echocardiography is a recent addition to the list
of imaging methods used for detection of myocardial viability.
In experimental and clinical studies, improvement in wall
motion with dobutamine stimulation has been found to be a
sensitive indicator of stunned but viable myocardium after
restoration of blood flow after acute ischemic injury (1,2). In
the setting of acute infarction treated with thrombolytic agents,
metabolic imaging and dobutamine echocardiography yield
similar results in distinguishing viable from infarcted myocar-
dium (3).
The phenomenon of myocardial hibernation—a reduction
in rest myocardial perfusion resulting in diminished left ven-
tricular contractility—is thought to account for systolic dys-
function in patients who have viable myocardium and chronic,
advanced coronary artery disease (4–6). The results of recently
published clinical studies suggest that dobutamine echocardi-
ography may also be useful for the detection of viable myocar-
dium in these patients with advanced coronary artery disease
and reduced left ventricular function (7–9). However, some
experimental observations suggest that dobutamine stimula-
tion may be less effective for the detection of viability when rest
myocardial perfusion is reduced (10).
Positron emission tomography (PET), by virtue of its ability
to assess myocardial perfusion and metabolism using
fluorine-18 fluorodeoxyglucose (FDG), is widely regarded as
the most accurate technique for the detection of viable myo-
cardium. A “mismatch” pattern, characterized by a reduction
in perfusion tracer uptake with normal or increased uptake of
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FDG, has been described as the PET correlate of myocardial
hibernation (5,11). In this investigation, patients with regional
wall motion abnormalities, reduced systolic function and ad-
vanced coronary artery disease underwent dobutamine echo-
cardiography and PET to identify the patterns of perfusion and
metabolism that occur in dobutamine-responsive myocardium.
This study also evaluated the accuracy of rest and dobutamine
echocardiography for the detection of myocardial viability
using metabolic imaging as the reference standard.
Methods
Patient selection. The Indiana University PET facility be-
gan operation in February 1993. Between February and No-
vember 1993, 53 patients with coronary artery disease and wall
motion abnormalities were evaluated for myocardial viability
at the facility. Twenty-six patients who also underwent dobut-
amine echocardiography for assessment of myocardial viability
comprised the study group. The viability studies were per-
formed at the discretion of the referring physician and written
informed consent was obtained for dobutamine echocardiog-
raphy. One subject who had a change in clinical status between
the two imaging studies was excluded.
In the remaining 25 patients (4 women, 21 men) the mean
age was 58 6 10 years and the average time between the
studies was 13 6 21 days. All patients had reduced left
ventricular systolic function (ejection fraction 32 6 9% [range
15% to 49%]). Eighteen patients had a history of prior
myocardial infarction. Five with a recent infarction (,4 weeks)
underwent PET from 5 to 11 days after the event. Eleven
patients had diabetes mellitus and 13 had hypertension.
Twenty-three patients were receiving medication to treat isch-
emia (nitrates in 22 patients, beta-blockers in 7 and calcium
antagonists in 6). Twelve patients had angina, and four of these
had worsened symptoms at the time of evaluation. No patients
had unstable angina. Nineteen patients had mild heart failure
symptoms (New York Heart Association functional class I or
II), and six had more severe symptoms (functional class III or
IV).
Positron emission tomography. Patients were requested to
fast for 4 to 6 h before the PET study. Oral glucose (50 g) was
administered before beginning the study. In patients with
diabetes mellitus, studies were performed with the patients on
their usual diet and medications. Plasma glucose levels were
monitored during the study, and if necessary, intravenous
insulin was administered to reduce glucose levels and enhance
FDG uptake. Positron emission tomography was performed
using a whole-body tomograph (Siemens 951/31R). A 15-min
transmission scan was performed after positioning the patient.
A 20-mCi dose of nitrogen-13 (N-13) ammonia was adminis-
tered intravenously for assessment of myocardial perfusion.
Beginning 5 min after injection, images were obtained for a
20-min period. After decay of the ammonia, 10 mCi of FDG
was administered. Thirty minutes after injection, images were
acquired for a 20-min period. For those patients with glucose
intolerance, FDG imaging was delayed until the plasma glu-
cose level was reduced by insulin administration. After treat-
ment, glucose levels were comparable between subjects with
and without glucose intolerance (106 6 25 mg/dl vs. 110 6
27 mg/dl, p 5 0.72). The image data were reconstructed using
a Hanning filter (cutoff frequency 0.35 cycles/pixel) to trans-
axial images, which were resliced into a series of short-axis and
long-axis images.
Dobutamine echocardiography. Echocardiograms were
performed using commercially available equipment (Hewlett
Packard Sonos 1500, Advanced Technology Laboratories
UM4). The modified Simpson method was used to obtain the
ejection fraction from the apical four-chamber view of the
baseline study in 24 subjects. In one subject the ejection
fraction was determined by visual assessment of the contrast
ventriculogram.
Intravenous dobutamine was infused in incremental fashion
starting at a dose of 5 mg/kg body weight per min. The dose was
increased to 10 mg/kg per min after 3 min and then by 10-mg/kg
per min increments every 3 min. End points for the infusion
included 1) extensive new or worsening wall motion abnormal-
ities; 2) chest pain; 3) $2 mm ST segment depression or
elevation; 4) significant side effects, arrhythmias or hypoten-
sion as determined by the operator; 5) $85% of the age-
predicted maximal heart rate; and 6) maximal dose of 50 mg/kg
per min. Intravenous atropine was administered in patients
who had minimal increases in heart rate at doses $30 mg/kg
per min. Echocardiographic images using parasternal and
apical windows were recorded on videotape and digitally
acquired in a quad screen format at baseline, at 5 and 10 mg/kg
per min and at peak dose in 21 patients, and at baseline,
10 mg/kg per min and peak dose in 4 other patients (12).
Analysis of PET images. Before initiation of this study, the
interobserver variability of visual assessment of the PET
images was determined by having two experienced observers
independently interpret the perfusion and metabolism studies
of 20 patients evaluated at our PET facility. The interobserver
agreement for distinguishing normal and reduced perfusion
was 84%. The interobserver agreement for determination of
viability based on FDG uptake was 92%. For the purposes of
this study, a single observer who had no knowledge of the
clinical data and the results of echocardiography visually
assessed and scored the uptake of N-13 ammonia and FDG in
16 left ventricular segments. The scheme used for segmenta-
tion of the left ventricle has been previously described (13).
Assessment of tracer uptake was made primarily from three
resliced short-axis images at the base of the left ventricle, at the
midpapillary muscle level and at the apex. The posterior
junction of the right and left ventricles, visible on the N-13
Abbreviations and Acronyms
FDG 5 fluorine-18 fluorodeoxyglucose
N-13 5 nitrogen-13
PET 5 positron emission tomography
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ammonia images, was used to define the location of the basal
and midinferior segments, and the locations of the remaining
basal and midventricular segments were determined using the
posterior and anterior (when visualized) junctions of the
ventricles as reference points.
Tracer uptake was graded using a four-point scale: 1 5
normal; 2 5 mildly reduced; 3 5 moderately reduced; 4 5
severely reduced or absent and equal to background activity
(14). For the purposes of this study, myocardial segments with
FDG scores $3 were considered to be nonviable and were
designated as having transmural infarction. Segments with
normal or mildly reduced FDG uptake were considered viable.
These segments were divided into three groups: Segments with
normal FDG uptake (51) in the presence of reduced N-13
ammonia uptake ($2), or mildly reduced FDG uptake (#2) in
the presence of moderate or severely reduced N-13 ammonia
uptake ($3) were defined as having perfusion-metabolism
mismatch. Segments with FDG and N-13 ammonia uptake
(52) were defined as having a pattern of nontransmural
infarction. Segments that had N-13 ammonia and FDG
scores 5 1 were designated as the normal N-13 ammonia,
normal FDG group. After completion of this study, a quanti-
tative method for determining tracer uptake was developed
and used to validate the visual scoring technique. Circumfer-
ential profiles of tracer uptake were derived in 15 subjects
using the semiautomated analysis program. Tracer uptake in
16 segments of the left ventricle was determined after normal-
ization of both the N-13 ammonia and FDG images to the
region having maximal ammonia uptake.
Analysis of echocardiographic images. Two observers, who
had no knowledge of the clinical data and results of PET
imaging, rendered a consensus analysis of wall motion at rest
and with dobutamine infusion in 16 left ventricular segments.
Wall motion was graded as 1 5 normal, hyperkinetic with
dobutamine; 2 5 mildly hypokinetic, ,5 mm inward systolic
motion; 2.5 5 severely hypokinetic minimal inward systolic
motion and wall thickening; 3 5 akinetic, absence of inward
motion and wall thickening; 4 5 dyskinetic. Improvement in
segmental wall motion by one grade or more (including severe
to mild hypokinesis) was considered significant. For the pur-
poses of comparison with the PET results, myocardial seg-
ments with scores #2.5 at rest or with dobutamine infusion
were considered viable.
Coronary angiography. Coronary angiography was per-
formed in all subjects. An experienced angiographer who had
no knowledge of the results of PET and echocardiographic
imaging determined percent diameter stenosis by caliper mea-
surement or visual estimation. Significant coronary artery
disease was defined by $50% reduction in lumen diameter of
an epicardial coronary artery or major branch vessel. Severe
disease was defined by $70% stenosis of a major vessel.
Statistical analysis. A preliminary analysis was performed
to determine if a segment by segment analysis of the data was
appropriate in the absence of any consistent intra-patient
correlations of the segment data. A total of 120 possible
correlations between the 16 left ventricular segments were
examined for each stage of the dobutamine echocardiographic
study and for the perfusion and metabolism data. The propor-
tion of segment pairs that had no statistically significant
correlation (p $ 0.05) was 73%, and in the remainder with
significant correlations both positive and negative correlations
were found. Because there were no consistent correlations, the
segment was used as the unit of analysis.
Continuous variables are reported as mean values 6 SD.
Mean values between different groups were compared using
the t test statistic. The Fisher exact test was used to analyze
categorical variables. The correlation between PET and echo-
cardiography for assessment of myocardial segment viability
was expressed as percent agreement and value of kappa. The
McNemar test was used in the analysis of discordant PET and
echocardiographic results. A p value ,0.05 was considered
significant.
Results
Dobutamine infusion and coronary angiography. Low and
peak dose echocardiographic studies were completed in all 25
subjects without complications. No patient had sustained ar-
rhythmia or prolonged ischemia resulting from dobutamine
infusion. Five patients received sublingual nitroglycerin or
esmolol, or both, to treat induced ischemia. The peak dose of
dobutamine was 40 6 10 mg/kg per min (range 20 to 50), and
eight subjects received atropine. The mean heart rate at
baseline was 776 15 beats/min and 1306 14 beats/min at peak
dose. The rate-pressure product was 8,980 6 2,265 mm Hg 3
beats/min at baseline, and 17,256 6 4,316 mm Hg 3 beats/min
at peak dose.
Twenty-one patients (84%) had multivessel and four had
single-vessel disease. Nineteen patients (76%) had $70%
stenosis of at least one coronary artery.
Positron emission tomography and dobutamine echocardi-
ography. Tracer uptake was quantitatively assessed in 15
patients to determine if the visual scoring system used in this
study reliably distinguished different groups of segments, in-
cluding those with reduced perfusion and those with mismatch.
Significantly greater N-13 ammonia uptake was seen in seg-
ments with normal (score 1) compared with mildly reduced
(score 2) perfusion (83 6 11% vs. 66 6 13%, p , 0.001).
Fluorine-18 FDG uptake was significantly greater in segments
with mildly reduced metabolism (score 2) (73 6 14%) com-
pared with tracer uptake in those scored as nonviable (scores
3 and 4) (606 14%, p5 0.006). The FDG/N-13 ammonia ratio
was significantly greater in segments with mismatch (1.53 6
0.42) compared with all other viable segments with reduced
perfusion (1.05 6 0.17, p , 0.001).
A total of 31 myocardial segments were excluded from
analysis because of inadequate echocardiographic or PET
images. Regional wall motion was assessed in the remaining
369 left ventricular segments. Baseline wall motion was abnor-
mal in 247 segments (67%) and normal in 122 segments.
Fluorine-18 FDG uptake indicative of myocardial viability was
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found in 192 dysfunctional segments (78%), and 55 segments
were nonviable according to PET criteria.
The perfusion and metabolism patterns in the 192 dysfunc-
tional segments with FDG evidence of myocardial viability are
shown in Figure 1. Segments with normal perfusion and
metabolism were most common. Only 14.5% of dysfunctional
segments had perfusion-metabolism mismatch. One segment
had normal perfusion and mildly reduced FDG uptake, and in
subsequent analyses this segment was included in the nontrans-
mural infarction group.
Improvement in wall motion at low doses of dobutamine (5
or 10 mg/kg per min) occurred in 62 (25%) of the 247
dysfunctional segments. An additional 27 (11%) improved at
peak dose. Fluorine-18 FDG evidence of myocardial viability
was found in 86 (97%) of the 89 segments that had improved
wall motion with dobutamine. Wall motion did not improve
with dobutamine stimulation in 158 dysfunctional segments. A
substantial but significantly smaller proportion of these seg-
ments (106 of 158 [67%]) had PET evidence of myocardial
viability compared with segments (86 of 89 [97%], p , 0.001)
that demonstrated improvement with dobutamine.
Each dysfunctional segment with PET evidence of myocar-
dial viability was assigned to one of three groups based on the
pattern of perfusion and metabolism, and the proportion of
segments with improvement in wall motion was determined
within each group. Figure 2 demonstrates that improvement in
wall motion was more common in the group of segments with
normal uptake of N-13 ammonia and FDG than in the groups
with reduced perfusion that had the patterns of nontransmural
infarction or mismatch.
Each dysfunctional segment that improved with dobut-
amine (n 5 89) was assigned to one of four categories that
characterized the low dose (5 or 10 mg/kg per min) and peak
dose changes in wall motion. Wall motion improved at low
dose and was unchanged at peak dose in 35 segments (39%).
Ten segments (11%) improved at low dose and continued to
improve at peak dose. Another 27 segments (30%) improved
only at peak dose, and 17 (19%) had a biphasic response,
improving at low dose and worsening at peak dose. The PET
results were compared in the four wall motion categories to
identify any associations between perfusion-metabolism pat-
terns and wall motion responses (Table 1). The few segments
with transmural infarction were found only in the two groups
(groups 2 and 3) that demonstrated improvement in wall
motion at peak dose. Normal perfusion and metabolism was
the most common pattern in each of the wall motion catego-
ries. The proportion of segments with normal perfusion and
metabolism was highest in the group with a biphasic response
(88% vs. 64% of segments in the other three groups, p5 0.08).
Fluorine-18 FDG evidence of myocardial viability was
present in all segments that exhibited a biphasic response. The
worsening of wall motion at peak dose suggested that these
segments had stress-induced ischemia and were likely to be
supplied by vessels with significant obstruction. The frequency
of severe disease ($70% diameter reduction) in vessels sup-
plying segments with a biphasic response was compared with
the frequency of severe disease supplying segments in the three
remaining categories that did not have stress-induced isch-
emia. Every segment having a biphasic response was supplied
by a vessel with severe stenosis (Fig. 3). The frequency of
severe stenosis in each of the groups without stress-induced
ischemia was significantly less than in the group with a biphasic
response.
Correlation of metabolic imaging and echocardiography
for detection of myocardial viability. The correlation between
metabolic imaging and echocardiography for identification of
myocardial viability and nonviability in the 369 segments
Figure 1. Perfusion and metabolism patterns in 192 dysfunctional
segments with PET evidence of viability. FDG 5 fluorine-18 fluoro-
deoxyglucose; NH3 5 nitrogen-13 ammonia; see text for definitions of
mismatch and nontransmural infarction.
Figure 2. Frequency of improvement with dobutamine in viable,
dysfunctional myocardial segments with different patterns of perfusion
and metabolism. Abbreviations as in Figure 1.
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analyzed is shown in Table 2. Segment viability was defined by
the presence of any inward motion on the baseline or dobut-
amine echocardiographic study. The PET criterion for seg-
ment viability was an FDG score #2. There was significant
agreement between PET and echocardiography for identifica-
tion of viable and nonviable segments (76.1% of segments,
kappa 5 0.362). Among discordant segments, more were
designated viable on PET and nonviable on echocardiography
compared with the number that were considered nonviable on
PET and viable on echocardiography (70 vs. 18 segments, p ,
0.001).
Discussion
Perfusion and metabolism patterns. The persistent dys-
function that is seen in patients with chronic and advanced
coronary artery disease is usually attributed to myocardial
hibernation. This phenomenon is characterized by a reduction
in rest myocardial perfusion and a concomitant reduction in
myocardial contractility. Hibernating myocardium may be
identified by PET on the basis of perfusion-metabolism mis-
match, the reduction of N-13 ammonia uptake in the presence
of preserved FDG uptake (5,11). In our study perfusion-
metabolism mismatch was present in ,15% of dysfunctional
segments that had PET evidence of myocardial viability. In the
majority of segments, both N-13 ammonia and FDG uptake
were scored as normal. These findings were unexpected in this
study group, which was composed primarily of patients with
severe, chronic disease and reduced ejection fraction. Previous
studies utilizing PET for detection of myocardial viability have
focused primarily on the analysis of mismatched segments.
However, in one of these studies normal perfusion and metab-
olism was also a common finding (61%) in dysfunctional but
viable segments (15). In a study by vom Dahl et al. (14),
mismatched segments also comprised a minority (37%) of the
dysfunctional segments with preserved metabolism. Persistent
contractile dysfunction in segments with normal perfusion may
result from stunning caused by repetitive episodes of ischemia
(5,16). In these studies of patients who have advanced coro-
nary artery disease, the frequency of segments with normal
perfusion suggests that the phenomenon of stunning may play
a significant role in the pathogenesis of persistent ventricular
dysfunction.
Detection of myocardial viability in normal and hypoper-
fused segments. The results of recent clinical studies have
suggested that dobutamine echocardiography has good sensi-
tivity for the detection of myocardial viability, even in patients
with severe coronary artery disease and left ventricular dys-
function (8,9). However, experimental evidence suggests that
dobutamine stimulation is less effective for the detection of
viability when rest myocardial perfusion is severely reduced
(10). In this situation, augmentation of contractility may be
prevented by a critical reduction in oxygen supply. Alterna-
tively, the magnitude of augmentation may be very transient or
below the threshold of detection by noninvasive imaging
(4,17). In our study, improvement of wall motion was more
commonly observed in segments that had normal perfusion
compared with those with mismatch and those with an equiv-
alent, mild reduction in both perfusion and metabolism. The
lack of improvement in segments with mismatch could be
attributed to the reduction in baseline perfusion. These results
Table 1. Perfusion and Metabolism Patterns in Myocardial Segments Improving With Dobutamine
PET Pattern
Wall Motion Response to Dobutamine
Improve Low, No
Change Peak
(n 5 35, group 1)
No Change Low,
Improve Peak
(n 5 27, group 2)
Improve Low,
Improve Peak
(n 5 10, group 3)
Improve Low,
Worse Peak
(n 5 17, group 4)
Normal NH3, normal
FDG
22 (63%) 18 (67%) 6 (60%)† 15 (88%)*
Nontransmural
infarction
9 (26%) 5 (18%) 1 (10%) 1 (6%)
Mismatch (s NH3,
a FDG)
4 (11%) 3 (11%) 1 (10%) 1 (6%)
Transmural infarction 0 (0%) 1 (4%)‡ 2 (20%)‡ 0 (0%)
*p 5 0.08, group 4 versus groups 1, 2 and 3. †p 5 0.047, group 3 versus group 4. ‡p 5 0.068, groups 2 and 3 versus
groups 1 and 4. FDG 5 fluorine-18 fluorodeoxyglucose; NH3 5 nitrogen-13 ammonia.
Figure 3. Proportion of segments improving with dobutamine that
were supplied by vessels with severe disease ($70% diameter stenosis).
CAD 5 coronary artery disease.
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would support the findings of Panza et al. (17), who reported
that the frequency of improvement with dobutamine declined
in proportion to the severity of perfusion abnormality. Our
results differ somewhat from the data reported by Perrone-
Filardi et al. (18), who found that dobutamine stimulation
maintained sensitivity (88%) for viability in segments with
thallium-201 uptake ,80% of maximal uptake. The disparity
in these results may be due to the different criteria used for
defining hypoperfused segments and the exclusive enrollment
of subjects with reduced left ventricular systolic function in our
study.
In our study segments that had mild reductions in both
perfusion and metabolism were also less likely to improve with
dobutamine, compared with segments with normal perfusion.
Segments with mild reductions in both perfusion and metab-
olism may fail to augment when there has been sufficient
subendocardial necrosis. The data of vom Dahl et al. (14),
showing that these segments are unlikely to improve in func-
tion after revascularization, support the hypothesis of infarc-
tion of the subendocardium, the portion of myocardium con-
tributing most to contractility (14).
Wall motion responses and perfusion-metabolism patterns.
Four patterns of low and peak dose changes in wall motion
were identified in segments that improved with dobutamine.
Segments with FDG uptake indicative of transmural infarction
were confined to the groups of segments demonstrating im-
provement at the peak dose of dobutamine. In a study of
patients with chronic coronary artery disease, Afridi et al. (19)
demonstrated that revascularization infrequently results in
improved wall motion of dysfunctional segments that augment
at peak doses of dobutamine. Our data suggest that the
majority of these segments have some viable tissue, and in a
small proportion (8%), tethering may account for the appear-
ance of viability during dobutamine stimulation.
A biphasic response to dobutamine, with improvement of
wall motion at low doses and subsequent worsening at peak
dose, is thought to occur in viable myocardium that becomes
ischemic with stress. Afridi et al. (19) reported that the
biphasic response was the wall motion pattern that best
predicted segments that had improved function after revascu-
larization. Their data suggest that the biphasic response iden-
tifies segments with substantial contractile reserve. Our results
are consistent with this hypothesis, as nearly all segments with
a biphasic response had normal perfusion, suggesting transmu-
ral viability. The proportion of segments with normal perfusion
was lower in every other category of wall motion response,
suggesting a lower frequency of transmural viability in these
categories. In our study, all segments that had a biphasic
response were subtended by a vessel with $70% stenosis,
lending credence to the hypothesis that the peak dose deteri-
oration of wall motion is a sign of induced ischemia. Addition-
ally, the observation that the biphasic response occurs in
normally perfused segments suggests that the rest dysfunction
in these segments could be due to stunning.
Echocardiography versus PET for detection of myocardial
viability. In our study, improvement of wall motion with
dobutamine was a specific finding for preserved FDG uptake.
However, improvement with dobutamine was not a sensitive
marker for preserved FDG uptake, as 19% of all segments had
PET evidence of viability but were considered nonviable
according to echocardiographic criteria. Baer et al. (20) have
previously reported that dobutamine stimulation underesti-
mates the number of segments with preserved FDG uptake.
The amount of viable tissue required to determine the pres-
ence of metabolic activity is likely to be less than that required
for detection of contractile reserve. In our study, a larger
proportion of segments with preserved FDG uptake failed to
improve with dobutamine. In contrast to the group studied by
Baer et al. (20), all of our subjects had global systolic dysfunc-
tion and extensive coronary artery disease and regional wall
motion abnormalities. Dobutamine stimulation may be less
sensitive when there are extensive areas of akinesia in combi-
nation with reduced perfusion (21). Additionally, other sys-
temic disorders, such as diabetes, may have contributed to
ventricular dysfunction. In nonischemic cardiomyopathy met-
abolic activity may be preserved, but contractile function may
be exhausted (22).
Study limitations. This study employed the standard pro-
tocol for assessment of myocardial viability and detection of
ischemia used in our laboratory. Echocardiographic imaging
was performed during two low dose stages (5 and 10 mg/kg per
min) and a peak dose stage (mean 40 6 10 mg/kg per min) of
dobutamine infusion. The majority of viable segments may be
detected using these two low dose stages, but other investiga-
tors have demonstrated the incremental value of additional
low dose stages (7.5 mg/kg per min) and intermediate doses (15
and 20 mg/kg per min) for detection of viability (10,17,19). We
may have underestimated the number of augmenting segments
by not capturing and analyzing intermediate dose stages.
This study used visual analysis for both wall motion and
tracer uptake. The results of quantitative analysis in a subset of
patients suggested that visual assessment of tracer uptake
defined different groups of segments. Qualitative analysis of
wall motion remains the standard in clinical practice.
For the purposes of this study, we categorized the results of
perfusion and metabolism imaging into several patterns.
Perfusion-metabolism mismatch may identify hibernating myo-
cardium, but stunned tissue and admixtures of viable and
Table 2. Positron Emission Tomographic and Echocardiographic
Detection of Myocardial Segment Viability
Echocardiography*
Viable Nonviable
PET
Viable 237 (64.2%) 70 (19.0%)†
Nonviable 18 (4.9%)† 44 (11.9%)
*Rest and dobutamine echocardiography: Probability that there is no
agreement between positron emission tomography (PET) and echocardiography
is p , 0.001, kappa 0.362. †p , 0.001: probability that the frequency of viable
segments on PET and nonviable segments on echocardiography is the same as
that for viable segments on echocardiography and nonviable segments on PET.
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necrotic tissue may also be found in regions of mismatch
(23,24). We also designated segments as having nontransmural
and transmural infarction based solely on the severity of re-
duction of perfusion and metabolism in the absence of patho-
logic data determining the true transmural extent of necrosis.
This study did not provide any information on the relative
merits of dobutamine stimulation and PET for predicting
improvement in contractile function after revascularization.
This topic may arguably be the most important to investigate,
but the primary purpose of this study was to examine patterns
of perfusion and metabolism in dysfunctional myocardium that
responds to dobutamine. Our study demonstrated that dobut-
amine stimulation underestimates the number of segments
with preserved FDG uptake. For prediction of functional
recovery, the results of recent studies suggest that the sensitiv-
ity of dobutamine stimulation is similar to that reported for
PET (8,9,14,15,18,21,23,25).
Conclusions. Normal perfusion and metabolism occurred
more frequently than mismatch, suggesting that myocardial
stunning may be more common than hibernation in this study
group with advanced coronary artery disease and left ventric-
ular dysfunction. Improvement of wall motion at both low and
peak doses of dobutamine was highly correlated with PET
evidence of myocardial viability. Improvement of wall motion
with dobutamine was more frequent in segments with normal
perfusion compared with those with patterns of mismatch or
nontransmural infarction. A biphasic response to dobutamine
was indicative of segments with normal perfusion, suggesting
transmural viability, and the presence of severe coronary artery
disease. Positron emission tomography and echocardiography
demonstrated fair agreement for detection of myocardial
viability, with PET identifying more segments as viable com-
pared with echocardiography.
We thank Patricia Brenneman and Ratnakar Amaravadi for their technical
assistance.
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